Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

To investigate the efficacy and tolerability of empagliflozin as an add-on to metformin therapy in patients with type 2 diabetes. Patients with HbA1c levels of ≥7% to ≤ 10% (≥53 to ≤86 mmol/mol) while receiving metformin (≥1,500 mg/day) were randomized and treated with once-daily treatment with empa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2014-06, Vol.37 (6), p.1650-1659
Hauptverfasser:	HÄRING, Hans-Ulrich, MERKER, Ludwig, SEEWALDT-BECKER, Elke, WEIMER, Marc, MEINICKE, Thomas, BROEDL, Uli C, WOERLE, Hans J
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzhydryl Compounds - therapeutic use Biological and medical sciences Blood Glucose - metabolism Blood Pressure Body Weight Cohort Studies Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Follow-Up Studies Glucosides - therapeutic use Glycated Hemoglobin A - analysis Glycemic index Humans Hypoglycemia Hypoglycemic Agents - therapeutic use Male Medical sciences Medical treatment Metabolic diseases Metformin - therapeutic use Middle Aged Time Factors Urinary tract diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!